Clinical Trials
21 trialsNCT00598351 2026-06-05
Natural History Study of Patients With Neurofibromatosis Type 2
National Institutes of Health Clinical Center (CC)
Recruiting
NCT07628647 2026-06-05
LWBC
University of Colorado, Denver
Phase NA Not yet recruiting
NCT06607692 2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT06639607 2026-06-03
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT03033992 2026-06-02
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
Children's Oncology Group
Phase NA Active not recruiting
NCT03213704 2026-06-02
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04903080 2026-06-02
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
Children's Oncology Group
Phase 1 Active not recruiting
NCT04978727 2026-06-02
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Phase 1 Active not recruiting
NCT03155620 2026-06-01
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03210714 2026-06-01
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01445288 2026-05-29
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Completed
NCT03251989 2026-05-29
Rare CNS Tumors Outcomes &Risk
National Institutes of Health Clinical Center (CC)
Completed
NCT04195555 2026-05-29
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03213652 2026-05-27
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03698994 2026-05-27
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04284774 2026-05-27
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04320888 2026-05-27
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07424092 2026-05-27
PED-DNX2401
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Recruiting
NCT03750513 2026-05-20
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03911388 2026-05-15
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07589361 2026-05-15
VBS-CSI-PT-PED
Ruijin Hospital
Not yet recruiting